

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date October 29, 2004

Frontier Building, 3601 C Street; Room 880/890

Agenda

Call in: 1-800-315-6338. Use access code 735#.

Drug classes to be discussed as time allows.

Call to order - Chair	Richard Brodsky, MD	8:00 a.m.
Introduce New P&T Committee Members	Richard Brodsky, MD	
Roll call	Richard Brodsky, MD	8:15 – 8:25
Public Comment – Local Public / Local Physicians - (See guidelines on page 2)		8:25 – 8:45
New Generation Antidepressants <ul style="list-style-type: none">Time for discussion & vote on New Generation AntidepressantsVote on motions	Terry Babb, Pharm D / FHSC	Time as needed
CNS Stimulants <ul style="list-style-type: none">Time for discussion & vote on CNS StimulantsVote on motions	Terry Babb, Pharm D / FHSC	Time as needed
Public Comment - (See guidelines on page 2)		9:10 – 9:30
Cox-II inhibitors <ul style="list-style-type: none">Time for discussion & vote on Cox-II inhibitorsVote on motions	Terry Babb, Pharm D / FHSC Presenter from EPC	
BREAK		Approx 10:00 a.m.
Public Comment - (See guidelines on page 2)		10:00 – 10:20
Serotonin Receptor Agonists <ul style="list-style-type: none">Time for discussion & vote on Serotonin Receptor AgonistsVote on motions	Terry Babb, Pharm D / FHSC Presenter from EPC	
Public Comment - (See guidelines on page 2)		10:40 – 11:00
Cholinesterase inhibitors <ul style="list-style-type: none">Time for discussion & vote on Cholinesterase inhibitorsVote on motions	Terry Babb, Pharm D / FHSC	
Public Comment - (See guidelines on page 2)		11:20 – 11:40
COPD Anticholinergics <ul style="list-style-type: none">Time for discussion & vote on COPD AnticholinergicsVote on motions	Terry Babb, Pharm D / FHSC	
Finalize Minutes - March & September Meetings	Richard Brodsky, MD	
Final Comments by Chair or other members		5 minutes
Closing		Noon or before

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
October 29, 2004

1. All interested speakers will be required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of five (5) minutes in total.
3. Only one speaker "slot" will be available per meeting representing a single manufacturer or interest group. Within the allowable five (5) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.